Mutation of the p51/p63 gene is associated with blastic crisis in chronic myelogenous leukemia
- PMID: 11681414
- DOI: 10.1038/sj.leu.2402265
Mutation of the p51/p63 gene is associated with blastic crisis in chronic myelogenous leukemia
Abstract
The p51/p63 gene, a novel member of the p53 gene family, has recently been identified at 3q27-9. There are at least six major isotypes of p51/p63 mRNA transcripts. p51A/TAp63gamma has the potential to induce apoptosis and growth suppression in a manner similar to p53, and other isotypes may suppress the p53 and p51A1TAp63gamma genes in a dominant-negative manner. We analyzed the mutation and expression of the p51/p63 gene in 80 cases of chronic myelogenous leukemia (CML) to evaluate its role in blastic transformation. Expression of the p51/p63 gene was detected in 74 cases. The alpha isotype of p51/p63 transcripts was dominantly expressed in 72 of these 74 cases. There was no correlation between the isotypes of p51/p63 transcripts and the clinical phase. Mutations of the p51/p63 gene were found in six cases. All these mutated cases expressed p51B/TAp63 alpha. In four of the six cases, the mutations were within a limited region (codon 151-170) corresponding to the DNA-binding domain. We hypothesized that this limited region is a hot spot for mutation of the p51/p63 gene. Mutations of the p53 gene were found in four cases of CML in blastic crisis (BC). Frequencies of the p51/p63 and p53 gene mutations were higher in BC (p51/p63 gene, 11.8%; p53 gene, 7.8%) than in the chronic phase (p51/p63 gene, 1.5%; p53 gene, 0%). The p51/p63 gene mutation may act similarly to the p53 gene mutation as a genetic alteration potentially responsible for the progression of CML.
Similar articles
-
Mutational analysis of p51A/TAp63gamma, a p53 homolog, in non-small cell lung cancer and breast cancer.Oncogene. 1999 Jun 24;18(25):3761-5. doi: 10.1038/sj.onc.1202972. Oncogene. 1999. PMID: 10391684
-
Effects of p51/p63 missense mutations on transcriptional activities of p53 downstream gene promoters.Cancer Res. 1999 Dec 1;59(23):5908-11. Cancer Res. 1999. PMID: 10606233
-
Frequent alteration of p63 expression in human primary bladder carcinomas.Cancer Res. 2000 Jul 1;60(13):3370-4. Cancer Res. 2000. PMID: 10910040
-
p53 family genes: structural comparison, expression and mutation.Cell Death Differ. 1999 Dec;6(12):1154-61. doi: 10.1038/sj.cdd.4400631. Cell Death Differ. 1999. PMID: 10637430 Review.
-
p63.Int J Biochem Cell Biol. 2002 Jan;34(1):6-9. doi: 10.1016/s1357-2725(01)00086-3. Int J Biochem Cell Biol. 2002. PMID: 11733180 Review.
Cited by
-
FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities.BMC Cancer. 2014 Jun 3;14:396. doi: 10.1186/1471-2407-14-396. BMC Cancer. 2014. PMID: 24893616 Free PMC article.
-
p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis.PLoS One. 2012;7(9):e45820. doi: 10.1371/journal.pone.0045820. Epub 2012 Sep 24. PLoS One. 2012. PMID: 23029260 Free PMC article.
-
Identification of DeltaN isoform and polyadenylation site choice variants in molluscan p63/p73-like homologues.Mar Biotechnol (NY). 2007 Mar-Apr;9(2):217-30. doi: 10.1007/s10126-006-6045-1. Epub 2007 Jan 22. Mar Biotechnol (NY). 2007. PMID: 17242983
-
Burkitt lymphoma in Brazil is characterized by geographically distinct clinicopathologic features.Am J Clin Pathol. 2008 Dec;130(6):946-56. doi: 10.1309/AJCP64YOHAWLUMPK. Am J Clin Pathol. 2008. PMID: 19019773 Free PMC article.
-
TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma.Blood. 2012 May 24;119(21):4949-52. doi: 10.1182/blood-2012-02-414441. Epub 2012 Apr 11. Blood. 2012. PMID: 22496164 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous